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ABSTRACT 28 
Study question: Which is the degree of patient satisfaction in women with symptomatic colorectal 29 
endometriosis who choose medical or surgical treatment after a shared decision making (SDM) 30 
process? 31 
Summary answer: The degree of satisfaction with treatment was high both in women who chose 32 
medical treatment with a low-dose oral contraceptive (OCP) or a progestin, and in those who chose 33 
to undergo surgical resection of bowel endometriosis. 34 
What is known already: Hormonal therapies and surgery for colorectal endometriosis have been 35 
investigated in non-comparative studies with inconsistent results.  36 
Study design, size, duration: Parallel cohort study conducted on 87 women referring to our centre 37 
with an indication to surgery for colorectal endometriosis. A standardised SDM process was 38 
adopted, allowing women to choose their preferred treatment. Median follow-up was 40 [18-60] 39 
months in the medical therapy group and 45 [30-67] in the surgery group.  40 
Participants, setting, methods: Patients with endometriosis infiltrating the proximal rectum, the 41 
rectosigmoid junction, and the sigmoid, not causing severe sub-occlusive symptoms were enrolled. 42 
A total of 50 patients chose treatment with an OCP (n = 12) or a progestin (n = 38), whereas 37 43 
women confirmed their previous indication to surgery. Patient satisfaction was graded according to 44 
a five-category scale. Variations in bowel and pain symptoms were measured by means of a 0 to 10 45 
numeric rating scale. Constipation was assessed with the Knowles-Eccersley-Scott Symptom 46 
Questionnaire (KESS), health-related quality of life with the Short Form-12 questionnaire (SF-12), 47 
psychological status with the Hospital Anxiety and Depression scale (HADS), and sexual 48 
functioning with the Female Sexual Function Index (FSFI).  49 
Main results and the role of chance: Six women in the medical therapy group requested surgery 50 
because of drug inefficacy (n = 3) or intolerance (n = 3). Seven major complications were observed 51 
in the surgery group (19%). At 12-month follow-up, 39 (78%) women in the medical therapy group 52 
were satisfied with their treatment, compared with 28 (76%) in the surgery group (adjusted OR, 53 
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1.37; 95% CI, 0.45 to 4.15; intention-to-treat analysis). Corresponding figures at final follow-up 54 
assessment were 72% in the former group and 65% in the latter one (adjusted OR, 1.74; 95% CI, 55 
0.62 to 4.85). The 60-month cumulative proportion of dissatisfaction-free participants was 71% in 56 
the medical therapy group compared with 61% in the surgery group (P = 0.61); the Hazard 57 
incidence rate ratio was 1.21 (95% CI, 0.57 to 2.62). Intestinal complaints were ameliorated by both 58 
treatments. Significant between-group differences in favour of medical treatment were observed at 59 
12-month follow-up in diarrhoea, dysmenorrhoea, non-menstrual pelvic pain, and SF-12 physical 60 
component scores. The total HADS score improved significantly in both groups, whereas the total 61 
FSFI score improved only in women who chose medical therapy.  62 
Limitations, reasons for caution: As treatments were not randomly assigned, selection bias and 63 
confounding are likely. The small sample size exposes to the risk of type II errors.  64 
Wider implications of the findings:  When adequately informed and empowered through a SDM 65 
process, most patients with non-occlusive colorectal endometriosis who had already received a 66 
surgical indication, preferred medical therapy. The possibility of choosing the preferred treatment 67 
may allow maximisation of the potential effect of the interventions.  68 
Study Funding/competing interest(s): This study was financed by Italian fiscal contribution 69 
"5x1000" - Ministero dell'Istruzione, dell'Università e della Ricerca - devolved to Fondazione 70 
Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, 71 
Milano, Italy. P.V., M.P.F., R.R., D.D., A.R., P.M., O.D.G., and M.C. declare that they have no 72 
conflicts of interest. E.S. received grants from Ferring and Serono. 73 
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INTRODUCTION 78 
Deep bowel endometriosis, i.e., endometriosis infiltrating at least the intestinal muscular layer 79 
(Chapron et al., 2006), appears to affect about one tenth of woman with endometriotic disease 80 
(Koninckx et al., 2012; Abrão et al., 2015). When endometriosis causes evident bowel obstruction, 81 
emergency surgery and segmental resection is the only reasonable choice.   82 
 However, most patients with deep bowel endometriosis complain of cyclic and non-cyclic 83 
symptoms, such as abdominal bloating, intestinal cramping, diarrhoea, and constipation, without 84 
obvious obstruction to stool passage. Symptoms may be associated not only with the degree of 85 
endometriotic infiltration and bowel lumen restriction, but also with lesion localization (Chapron et 86 
al., 2006; Roman et al., 2012). The rectosigmoid colon is the most frequently involved intestinal 87 
tract, followed by isolated nodules of the proximal sigmoid, and by lesions of the terminal ileus and 88 
cecum (Vercellini et al., 2004; Abrão et al., 2015; Roman et al., 2017a).  89 
 According to some authors, excisional surgery is the best solution for women with 90 
symptomatic intestinal endometriosis, as medical treatments may exert an effect on the endometrial 91 
and smooth muscle component of the nodule, but not on the extensive fibrotic component, thus 92 
providing limited benefit (Remorgida et al., 2007; Minelli et al., 2009; Abrão et al., 2015; Milone 93 
et al., 2015). However, several investigators observed substantial improvements of bowel 94 
symptoms during treatment with low-dose, monophasic oral contraceptive pills (OCP) or progestins 95 
(Ferrero et al., 2010a, 2010b; Ferrari et al., 2012; Yela et al., 2015; Leonardo-Pinto et al., 2017). 96 
Egekvist et al. (2017) reported that 56% of 238 women with symptomatic rectosigmoid 97 
endometriosis eventually avoided surgery by using OCPs or progestins. 98 
 Disentangling the uncertainties on the role of medical therapy in women with this 99 
infiltrating endometriosis form is exceedingly important, as excisional procedures with opening of 100 
the bowel lumen are generally effective in relieving intestinal symptoms, but are also associated 101 
with severe short- and long-term complications. 102 
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 Only non-comparative studies are available on treatment of intestinal endometriosis with 103 
either medical therapy or surgery. Participants are being recruited in a French randomised, 104 
controlled trial comparing medical and surgical treatment for rectal endometriosis, but results will 105 
be available at the end of 2019 106 
(https://www.clinicaltrials.gov/ct2/show/NCT01973816?term=endometriosis+AND+France&draw107 
=4&rank=24. Accessed on October 1, 2017). 108 
 In our centre, a consistent shared decision making (SDM) approach is systematically applied 109 
whenever a complex choice should be made between medical and surgical treatment in the absence 110 
of robust evidence demonstrating definite advantages of one therapeutic balance over the other. 111 
Therefore, we deemed it important to evaluate the impact of this process on patients who had 112 
already received an indication for excision of deep endometriosis infiltrating the rectosigmoid 113 
colon, and to assess the effectiveness of hormonal manipulation and surgery in relieving bowel 114 
symptoms in women who chose their preferred option.  115 
 The primary end-point of the study was patient satisfaction with treatment. Variations in 116 
intestinal and pain symptoms, sexual functioning, psychological status, and health-related quality of 117 
life were also assessed. 118 
 119 
MATERIALS AND METHODS 120 
This parallel cohort study evaluated the medium- (12 months) and long-term outcomes (> 12 121 
months) of two therapeutic alternatives, that is, long-term treatment with a low-dose, monophasic 122 
OCP or a progestin, and excisional surgery, for symptomatic deep bowel endometriosis infiltrating 123 
the sigmoid colon, the rectosigmoid junction or the proximal rectum. The study was conducted 124 
retrospectively on prospectively and systematically recorded data. The investigation, performed in 125 
an academic department specialising in endometriosis management, was approved by the local 126 
institutional review board (Comitato di Etica Milano Area B; determination #1123/2017). All 127 
patients signed a written consent for participation in the study.  128 
Vercellini et al., 6 
Study population 129 
 We considered 18–50-year-old women not wanting pregnancy, who received an indication 130 
for surgical excision of intestinal endometriosis, and were referred to our centre between January 131 
2011 and January 2016 for an expert opinion or for performing the surgical procedure. The 132 
diagnosis of deep intestinal endometriosis was based on rectal endosonography to define the level 133 
of rectal involvement and to determine the depth of rectal wall infiltration; double-contrast barium 134 
enema to ascertain the presence and degree of colorectal stenosis; colonoscopy or sigmoidoscopy to 135 
exclude chronic inflammatory bowel diseases and malignancies and investigate additional proximal 136 
localisations in selected circumstances; and magnetic resonance imaging and CT colonography to 137 
better define the overall anatomic conditions of the affected bowel tract and associated 138 
endometriotic pelvic lesions in some women. The diagnostic work-up includes kidney and urinary 139 
tract ultrasonography to rule out hydro-utereronephrosis and bladder nodules. 140 
 Subjects with persistent, cyclic or non-cyclic intestinal symptoms of more than 6 141 
months’ duration, and an instrumental diagnosis of endometriosis infiltrating the muscular layer of 142 
the proximal rectal tract (≥ 8 cm from the anal verge), the rectosigmoid junction (13 to 15 cm from 143 
the anal verge) and the sigmoid (> 15 cm from the anal verge) were deemed eligible for the study. 144 
Nodules of the distal rectum (within 8 cm from the anal verge) were not included, as generally they 145 
are part of rectovaginal endometriosis forms and, in our opinion, should be considered separately. 146 
(Vercellini et al., 2009a). Exclusion criteria were: bowel stenosis associated with obstinate sub-147 
occlusive symptoms (e.g., nausea and vomiting not limited to the days of menstruation, frequent 148 
episodes of colicky pain with abdominal distension (> 1 per month), habitual emission of small-149 
calibre stool); detection of  ≥ 60% stenosis of the bowel lumen independently of subocclusive 150 
symptoms (Figure 1); previous surgery for intestinal endometriosis; previous endoscopy-based 151 
diagnosis of chronic inflammatory bowel diseases (Crohn's disease; ulcerative colitis); evidence of 152 
complex adnexal cysts or an ovarian endometrioma of diameter  > 4 cm at vaginal ultrasonography; 153 
the typical contraindications to oestrogen-progestins; and unwillingness to tolerate menstrual 154 
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changes. Previous surgery for endometriosis not involving the bowel was not considered an 155 
exclusion criterion.  156 
Treatments 157 
 In case of symptomatic bowel endometriosis, women are informed that data supporting the 158 
efficacy of hormonal therapies for the relief of intestinal symptoms, although generally favourable, 159 
do not allow to draw conclusions on long-term outcomes, as they are derived from non-comparative 160 
observational studies with short periods of treatment. They are also informed that medical therapies 161 
for endometriosis induce only temporary relief, are not expected to be definitively curative, and 162 
may cause several side effects. Finally, when hormonal treatments are to be continued for long 163 
periods, oestrogen-progestins and progestins appear to be among the compounds that most 164 
favourably balance benefits, harm and costs (Vercellini et al., 2011).  165 
 Patients are informed that surgery is currently considered the standard treatment for severely 166 
symptomatic bowel endometriosis; according to published evidence, excision of the affected 167 
intestinal area and segmental colorectal resection substantially improve bowel complaints and 168 
health-related quality of life, but are associated with major complications.  169 
 For the present study, two groups of participants with deep intestinal endometriosis were 170 
eventually generated in whom motivational factors were optimized by allowing them to receive 171 
their preferred treatment. Thus, the selected therapeutic modality was not by random allocation. In 172 
women opting for medical therapy, the SDM process remained open during the treatment period, 173 
allowing women to request surgery at any time.  174 
 Participants who chose hormonal treatment were instructed to take a low-dose, monophasic 175 
OCP or a progestin starting on the first day of menstruation. In case an OCP was chosen, a 176 
combination containing ethinylestradiol 0.015 mg and gestodene 60 mg per pill was prescribed. 177 
Women were instructed to use the OCP continuously. In case a progestin was preferred, oral 178 
norethisterone acetate (NETA), 2.5 mg once a day (Ferrero et al., 2010b), or oral dienogest, 2 mg 179 
once a day, was administered. In case of prolonged spotting (≥7 days) or breakthrough bleeding 180 
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during continuous hormonal therapy, the women were advised to discontinue treatment for 4 days 181 
(OCP users) or 1 week (NETA users). They were also allowed to use psyllium twice a day and to 182 
take NSAIDs when needed. 183 
 Surgical procedures were performed at laparoscopy or laparotomy based on the caring 184 
abdominal surgeon's advice and according to previously described standard techniques (Fedele et 185 
al., 2004; Vercellini et al., 2009b). Segmental resection was generally preferred in patients with 186 
extensive intestinal infiltration, limiting disk excision to cases of small or well-defined nodules. The 187 
decision to carry out a diverting ostomy was taken intra-operatively and based on individual bowel 188 
anatomic conditions. Gynaecologists treated associated pelvic endometriotic lesions as usual 189 
(Vercellini et al., 2009b). After surgery, patients were advised to use postoperative medical therapy 190 
with a low-dose OCP or a progestin with the objective of limiting the risk of symptom and lesion 191 
recurrence (Seracchioli et al., 2009). 192 
Measurements 193 
In all patients referring to our centre, demographic information and a medical history are 194 
systematically obtained at baseline screening. Follow-up clinical and ultrasonographic evaluation 195 
are scheduled every 6 months. On these occasions, women are routinely asked to complete several 196 
questionnaires. For this study, two were on intestinal symptomatology (a numeric rating scale, 197 
NRS; and the Knowles-Eccersley-Scott Symptom Questionnaire, KESS), one on pain (a NRS), one 198 
on quality of life (the Short Form-12 questionnaire, SF-12), one on psychological status (the 199 
Hospital Anxiety and Depression scale, HADS), and one on sexual functioning (the Female Sexual 200 
Function Index, FSFI).  201 
 With the first questionnaire on intestinal symptoms, originally published by Ferrero et al. 202 
(2010b), the severity of each symptom is assessed by a 11-point numeric rating scale, with 0 203 
indicating absence of symptom, and 10 symptom that is as severe as it can be. 204 
 The KESS questionnaire (Knowles et al., 2000, 2002) is a well-recognised, validated, self-205 
report, multidimensional, instrument, originally developed to diagnose constipation, that allows to 206 
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discriminate among pathophysiological sub-groups. The questionnaire is composed of 11 questions 207 
with four or five mutually exclusive answers and corresponding 0 to 3 or 0 to 4 scores. Item scores 208 
are summed to deliver a total score ranging from 0 to 39, with higher scores indicating higher 209 
symptom severity. A score of 10 or over indicates the existence of constipation (Knowles et al., 210 
2000).  211 
 Patients are also asked to complete a questionnaire on the presence and severity of 212 
dysmenorrhoea, deep dyspareunia, non-menstrual pelvic pain, and dyschesia using an 11-point 213 
numeric rating scale, with 0 indicating the absence of pain and 10 indicating pain that is as bad as it 214 
can be. A score of 1 to 5 is considered mild pain, from 6 to 8 moderate pain, and over 8 severe pain. 215 
The SF-12, HADS, and FSFI have been described previously in detail (Vercellini et al., 2016).  216 
 Briefly, the SF-12 health survey, developed from the original SF-36 questionnaire (Ware 217 
and Sherbourne, 1992; McHorney et al., 1993), is a well know, validated self-administered 12-item 218 
instrument. It measures health dimensions covering functional status, well-being, and overall health 219 
to construct physical (PCS-12) and mental (MCS-12) component summary measures (Ware et al., 220 
1996; Gandek et al., 1998), with higher scores indicating better health perception. 221 
 The HADS questionnaire is a self-assessment mood scale to determine states of anxiety and 222 
depression. It comprises 14 questions, 7 for the anxiety subscale and 7 for the depression subscale. 223 
Lower scores indicates better psychological status (Zigmond and Snaith, 1983). 224 
 The FSFI questionnaire is a 19-item, multidimensional, self-report instrument for evaluating 225 
the main categories of female sexual dysfunction and sexual satisfaction (Rosen et al., 2000; 226 
Meston, 2003; Wiegel et al., 2005). The maximum (best) transformed full-scale score is 36, with a 227 
minimum full-scale score of 2.0.  228 
 Women using hormone therapies are asked to indicate the occurrence of side effects. 229 
Irregular bleeding during medical treatment is defined as spotting (scanty bleeding requiring ≤1 230 
pads or tampons per day) or breakthrough bleeding (light or moderate bleeding requiring ≥ 2 pads 231 
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or tampons per day). Pain during spotting or breakthrough bleeding is considered to be 232 
dysmenorrhea. 233 
 At each follow-up visit, patients routinely rate the degree of satisfaction with their treatment 234 
according to a 5-category scale (very satisfied, satisfied, neither satisfied nor dissatisfied, 235 
dissatisfied, or very dissatisfied) by answering the following question: ‘‘Taking into consideration 236 
the variations that occurred in intestinal and pain symptoms, overall physical and psychological 237 
well-being, health-related quality of life, and sexual functioning, how would you define the level of 238 
satisfaction with your current treatment?’’ 239 
Data management  240 
Data were archived using Excel 2003 (Microsoft Corporation, Redmond, Washington, U.S.A.) and 241 
exported in SPSS 18.0 (SPSS, Inc, Chicago, IL, U.S.A.) or SAS software 9.4 (SF-12 data; SAS 242 
Institute Inc., Cary, NC, U.S.A.) for statistical analysis. The focus of the investigation was not on a 243 
head-to-head comparison between the two treatment alternatives. The study question was "how 244 
many women with a surgical indication for symptomatic deep bowel endometriosis chose medical 245 
therapy instead of surgery after undergoing a shared decision making process, and how many of 246 
these are satisfied with their treatment at long-term follow-up evaluation?" As treatment allocation 247 
was based on patient preference, distribution of participants between the two study groups was 248 
expectedly unbalanced (Vercellini et al., 2012). Moreover, no comparative studies on the effect of 249 
medical therapy and surgery for symptomatic bowel endometriosis have yet been published. 250 
Available case series demonstrated substantially similar benefits of the two therapeutic alternatives 251 
(Ferrero et al., 2010a e 2010b; Minelli et al., 2009; Darai et al., 2010), thus impeding the definition 252 
of a clinically important between-group difference in the main outcome. For these reasons, a pre-253 
planned power calculation was not performed, and we decided to include all the eligible patients 254 
evaluated in a quinquennium. 255 
 In order to estimate the effect of treatment on patient satisfaction, a dichotomization of the 256 
outcome into treatment success (very satisfied plus satisfied subjects) and treatment failure (neither 257 
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satisfied nor dissatisfied plus dissatisfied plus very dissatisfied subjects) was done. The statistical 258 
significance of differences in patient satisfaction rates was compared using Fisher's exact test, and 259 
the analysis was performed according to the intention-to-treat principle. Dropouts were considered 260 
as treatment failures (dissatisfied) and included in this analysis. A logistic regression model 261 
including terms for age, previous surgery for endometriosis, the number and dimension of the 262 
endometriotic lesions and characteristics found to differ (P < 0.05) at baseline univariate analysis, 263 
were used to calculate the adjusted odds ratio (OR) for being dissatisfied (very dissatisfied, 264 
dissatisfied, or neither satisfied nor dissatisfied) with the use of medical therapy compared with 265 
surgery. Time to dissatisfaction with the treatment chosen was analysed with the product limit 266 
method and the curves obtained were compared by the log-rank test. Subjects deciding to seek 267 
conception were censored. The event data used in computing time to dissatisfaction with treatment 268 
were the date of medical therapy commencement or surgery, and the date of study questionnaires 269 
completion with indication of dissatisfaction or uncertainty, or last follow-up visit.  270 
Baseline characteristics of the patients were compared using Fisher's exact test, Mann-Whitney test, 271 
or unpaired Student's t-test, as appropriate. The distribution of the studied variables was assessed 272 
using the Shapiro-Wilk test. Normally distributed variables were reported as mean ± SD and 273 
compared using unpaired Student t-test, paired Student t-test or ANOVA for repeated measures, as 274 
appropriate. Non-normally distributed variables were reported as median (interquartile range) and 275 
compared using Mann-Whitney test, paired Wilcoxon test and Friedman test, as appropriate. All 276 
statistical tests were two-sided, and P < 0.05 was considered statistically significant. 277 
 278 
RESULTS 279 
In the quinquennium 2011-2016, 146 patients with symptomatic colorectal endometriosis were 280 
evaluated and counselled in our centre. A total of 59 women were excluded for various reasons 281 
(Figure 3). After the completion of the SDM process, 50 (57%) patients decided not to undergo 282 
surgery and try medical treatment, whereas 37 (43%) confirmed their preference for the previously 283 
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received surgical indication. The median [interquartile range] follow-up period was 40 [18-60] 284 
months for women who chose medical therapy and 45 [30-67] months for those who chose surgery. 285 
Recruitment and women's progress through the study is shown in Figure 2. The demographic and 286 
clinical characteristics of participants in the two study groups are shown in Table I. The distribution 287 
of the considered variables was similar. In the majority of cases the endometriotic nodule infiltrated 288 
the rectosigmoid junction and in four women out of ten the upper rectum. An isolated sigmoid 289 
nodule was identified in only 6 patients. More than one nodule was detected in one fifth of the 290 
participants. The mean diameter of the largest nodule was slightly over 3 cm in the medical 291 
treatment group, and 3.5 cm in the surgery group (P = 0.15). Additional major endometriotic 292 
lesions (uterosacral, rectovaginal and bladder nodules, ovarian endometriomas) were present in 21 293 
(42%) women in the medical treatment group and in 13 (35%) in the surgery group (P = 0.51). 294 
 A total of 12 (24%) women who chose medical therapy used the low-dose OCP, and 38 295 
(76%) a progestin (NETA, n = 29; dienogest, n = 9). Side effects were very common, and were 296 
experienced by 37 (74%) women. The most frequently reported untoward effects were weight gain 297 
(n = 16), decreased libido (n = 9), bloating (n = 8), vaginal dryness (n = 8), headache (n = 5), and 298 
mood changes (n = 2). However, side effects were severe enough to cause withdrawal from the 299 
study in only three women (weight gain, n = 1; headache, n = 1; mood changes, n = 1).  300 
 Surgery was performed at laparoscopy in nine women (24%) and at laparotomy in 28 (76%). 301 
The vast majority of patients (92%) underwent segmental resection (Supplementary Table S I). The 302 
mean length of the resected bowel segment was 13 ± 6 cm. Two distinct intestinal tracts were 303 
resected in seven women. An end-to-end, and end-to-side anastomosis was performed in, 304 
respectively, 91% and 9%, of the cases. Disk excision was performed in only 3 women. A diverting 305 
ileostomy has been created in three patients, and a colostomy in two. Additional endometriotic 306 
lesions were excised in all subjects. Histology confirmed endometriotic infiltration of the muscular 307 
layer in 27 patients, of the sub-mucosal layer in 8, and of the intestinal mucosa in 2. No major intra-308 
operative complications occurred. Six (16%) major post-operative complications were observed 309 
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necessitating immediate (intestinal anastomosis dehiscence, n = 2; haemoperitoneum, n = 2) or 310 
delayed (rectovaginal fistula formation, n = 1; colostomy occlusion, n = 1) re-intervention. One 311 
woman developed severe dysfunctional constipation caused by iatrogenic splancnic denervation. 312 
Twenty women (54%) used prolonged postoperative medical treatment (OCP, n = 8; NETA, n = 9; 313 
dienogest, n = 3).  314 
Satisfaction with treatment 315 
Seven women in the medical treatment group and one in the surgery group withdrew from the study 316 
for various reasons (Figure 2). All these women, including one in the former group that 317 
discontinued therapy to seek a conception, were considered as failures (dissatisfied) in the 318 
evaluation of satisfaction with treatment, the primary end-point of our study. 319 
 At 12-month follow-up, 11 (22%) women in the medical therapy group were very satisfied 320 
with their treatment, 28 (56%) satisfied, 4 (8%) neither satisfied nor dissatisfied, 6 (12%) 321 
dissatisfied, and 1 (2%) very dissatisfied. Corresponding figures in the surgery group were, 322 
respectively, 11 (30%), 17 (46%), 3 (8%), 1 (3%), and 5 (13%). Overall, at 12-month follow-up 323 
78% of women who chose medical therapy was satisfied or very satisfied with the treatment 324 
received, compared with 76% of those who chose surgery (OR, 1.14; 95% CI, 0.42 to 3.12. 325 
Adjusted OR, 1.37; 95% CI, 0.45 to 4.15). Corresponding figures at final follow-up assessment 326 
were 72% in the medical treatment group (very satisfied, n = 14; satisfied, n = 22; neither satisfied 327 
nor dissatisfied, n = 5; dissatisfied, n = 7; very dissatisfied, n = 2), and 65% in the surgery group 328 
(very satisfied, n = 11; satisfied, n = 13; neither satisfied nor dissatisfied, n = 4; dissatisfied, n = 6; 329 
very dissatisfied, n = 3) (OR, 1.39; 95% CI, 0.56 to 3.48. Adjusted OR, 1.74; 95% CI, 0.62 to 4.85).  330 
 Dissatisfaction-free survival analysis is shown in Figure 3. The 60-month cumulative 331 
proportion of subjects free from dissatisfaction (satisfied with the treatment received) was 71% in 332 
the medical therapy group, compared with 61% in the surgery group (log-rank test, 21 = 0.25; P = 333 
0.61). The incidence rate ratio (IRR) of dissatisfaction in operated women was 1.21 (95% CI, 0.57 334 
to 2.62). 335 
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Effect on bowel symptoms 336 
At baseline, diarrhoea, catamenial diarrhoea, and intestinal cramping NRS scores were significantly 337 
higher in the surgery group compared to the medical treatment group (Table II). These variables 338 
were included in the multivariable model used to analyse the primary outcome. The frequency of 339 
the remaining bowel symptoms did not differ between the study groups.  340 
 All studied symptoms significantly improved in both study groups with the exception of 341 
diarrhoea in operated women (P = 0.10). At 12-month follow-up and at the end of the follow-up the 342 
NRS scores of the studied symptoms were similar between women choosing for medical therapy 343 
and those opting for surgery with, again, the exception of diarrhoea that resulted worse in operated 344 
women (Table II). 345 
 Considering the KESS score, a significantly improvement occurred in both groups (Table 346 
III). Moreover, we failed to identify any significant difference between the two groups at study 347 
entry, at 12-month follow-up and at the last assessment. 348 
Effect on pain, health-related quality of life, psychological status, and sexual functioning 349 
Dysmenorrhoea, deep dyspareunia, non-menstrual pelvic pain and dyschesia did not differ between 350 
the study groups at baseline evaluation (Table IV). All these symptoms improved in both treatments 351 
groups. However, the magnitude of the beneficial effects was more pronounced in women choosing 352 
medical therapy, in particular for dysmenorrhea and for non-menstrual pain. At baseline, 94% of the 353 
women in the medical treatment group used non-opioid analgesics compared with 84% in the 354 
surgery group. The respective proportions at 12-month and last follow-up assessment were 24% and 355 
23% in the medical treatment group, and 51% and 47% in the surgery group (P = 0.02). 356 
 Mean SF-12 scores increased (improved) significantly in both groups at both 12-month and 357 
last follow-up evaluation (Table III). Also psychological status improved in both groups without 358 
significant between-group difference (Supplementary Table S II). Minor variations were observed 359 
in the mean total FSFI score. However, in both study groups the mean total FSFI score was well 360 
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below the physiologic cut-off score (26.55) at both 12-month and last follow-up evaluation 361 
(Supplementary Table S II).   362 
 363 
DISCUSSION 364 
More than two thirds of women who chose long-term medical therapy were satisfied with their 365 
treatment after a median follow-up of more than three years, a proportion similar to that observed in 366 
women who chose surgery. Including one woman lost to follow-up, only 6/50 (12%) patients 367 
requested surgery because of inefficacy of (n = 3), or intolerance to OCP and progestins (n = 3). 368 
Another 7 (14%) women were not satisfied with their therapy, but preferred to continue their 369 
medications instead of undergoing surgery.  370 
 It would had been of importance to ask the patients also whether their overall health became 371 
better or worse since last time they answered the questionnaires. However, the question on which 372 
the participants formulated their judgment on the degree of satisfaction with treatment at each 373 
follow-up visit was inclusive of variations in intestinal and pain symptoms, overall physical and 374 
psychological well-being, health-related quality of life, and sexual functioning.  375 
 Most women with symptomatic bowel endometriosis, when thoroughly informed on 376 
potential benefits, risks, and drawbacks of medical and surgical treatment, expressed their 377 
preference for the former option, thus confirming that patients who engage in SDM tend to choose 378 
nonsurgical treatment alternatives (Vercellini et al., 2012; Spatz et al., 2017). It may not be 379 
excluded that, had they not already received a surgical indication, the proportion of patients 380 
choosing medical therapy could have been even higher. On the other hand, the opposite could have 381 
been true, had colorectal resection be systematically offered at laparoscopy instead of laparotomy.   382 
 The incidence of side effects reported by women who chose OCP and progestins was 383 
unusually high. However, only 3/50 women requested surgery because of drug intolerance. Also the 384 
incidence of surgical complications was high, as six women underwent repeat surgery and one 385 
developed permanent severe iatrogenic constipation. Thus, the potential benefits and potential 386 
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harms of the two options depict very different therapeutic balances, thus suggesting that, in women 387 
with colorectal endometriosis not seeking pregnancy, “surgery is the therapy of choice for 388 
symptomatic patients when deep lesions do not improve with a medical treatment" (Abrão et al., 389 
2015).  390 
 Owing to the intrinsic methodological limitations of the design of the present study, we are 391 
unable to accurately define and reliably compare the respective effect size of the two treatment 392 
options. Taking this shortcoming into account, low-dose, monophasic OCPs and progestins 393 
successfully controlled symptoms associated with infiltrating colorectal endometriosis in the 394 
majority of patients who preferred a conservative approach, and this result appears aligned with the 395 
priorities and expectations of these women. What we have observed could be considered the 396 
maximum possible effect obtainable in similar clinical conditions when using medical therapy in 397 
those patients that have chosen their treatment.  398 
 However, it should be emphasized that, precisely in everyday practice, the alternative 399 
between medical and surgical treatment could be proposed in only about two thirds of patients with 400 
colorectal endometriosis, as 37 could not choose because of severe intestinal stenosis. Moreover, 401 
six of the 50 women who chose hormonal treatments discontinued them owing to drug inefficacy or 402 
intolerance. This means that medical therapy could be used successfully in no more than half of the 403 
women with colorectal endometriosis evaluated in our centre during the index period. In addition, 404 
the population enrolled in our study was rather young. Elderly women may bleed more frequently 405 
under medical treatment, likely owing to adenomyosis, and be more prone to ask a surgical option 406 
after several months of medical treatment. 407 
 In comparison with recently published evidence, in our study laparoscopy and disk excision 408 
were underused. The decision between laparoscopy and laparotomy, as well as on the type of bowel 409 
procedure to perform, were taken by abdominal surgeons based on their knowledge, experience, 410 
and advice. The rate of open surgery in our series was very high, and it may not be excluded that 411 
with a systematic laparoscopic approach the incidence of complications and the proportion of 412 
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satisfied patients could have been better. On the other hand, the majority of women who underwent 413 
surgery, also used long-term postoperative medical therapy with OCP or progestins. Therefore, the 414 
effect of surgery on intestinal and pelvic pain symptoms was likely overestimated, as it is not 415 
possible to discriminate between the effect of the two therapeutic components when they are 416 
combined. 417 
 Medical treatment improved irritative-type symptoms and also constipation, although to a 418 
lesser extent. The resolution of cyclic inflammation due to intra- and peri-lesional micro-419 
haemorrhages may explain the effect of hormonal compounds on irritative complaints. In fact, the 420 
responsiveness of deep intestinal lesions to progestins is supported by demonstration of 421 
progesterone receptors in ectopic glands infiltrating the muscular layer of the bowel wall (Noël et 422 
al, 2010). In theory, constipation may originate from fibrosis, which should be unresponsive to 423 
medical therapy, but also from altered innervation, which cannot be restored (or may even be 424 
worsened) by surgery (Milone et al., 2015). In these cases, also surgery seems less effective on 425 
constipation than on other types of bowel symptoms (Roman et al., 2013a, 2016, 2017b). According 426 
to Roman et al. (2013a; 2013b), here colorectal resection may not substantially improve bowel 427 
complaints (Riiskjaer et al., 2016), and Kupelian and Cutner (2016) suggest that surgeons should 428 
not offer segmental resection based on the expectation that digestive outcomes will improve. 429 
 A possible explanation for the somewhat unexpected effect of medical therapy on 430 
constipation observed in our study, might be a decrease in nodule size that may partially relieve the 431 
reduction in lumen caliber of the affected bowel tract (Ferrari et al., 2012). In this regard, our 432 
experience is not fully consistent with that of other authors (Ferrero et al., 2010b; Leonardo-Pinto et 433 
al., 2017).  434 
 The observed larger effect of OCP and progestins over surgery on dysmenorrhoea was 435 
expected, as menstruations were abolished in most women who chose medical therapy. However, 436 
dysmenorrhoea is a non-specific symptom, and it is not a reliable parameter to assess the efficacy of 437 
surgery for colorectal endometriosis. More interesting is the effect of medical therapy on deep 438 
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dyspareunia that confirms our previous findings in patients suffering from severe pain at intercourse 439 
(Vercellini et al., 2012). Improvements in health-related quality of life, psychological status, and 440 
sexual function were similar in the two study groups, but it may not be excluded that surgical 441 
outcomes could have been better if all the procedures had been performed at laparoscopy.   442 
 In conclusion, long-term treatment with a low-dose OCP or a progestin should be 443 
systematically included among the therapeutic options for women not seeking a conception with 444 
bowel endometriosis and without persistent and severe sub-occlusive symptoms. Surgery should be 445 
considered as a second-line treatment reserved to those patients not responding to, not tolerating, or 446 
with contraindications to low-dose OCP and progestins. However, the final decision should be 447 
made together with the woman, respecting her priorities and preferences.448 
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FIGURE LEGENDS  579 
 580 
Figure 1. Barium enema demonstrating deep endometriotic infiltration of the rectosigmoid 581 
junction with lumen stenosis (arrow). 582 
 583 
Figure 2. Flow chart showing recruitment and women's progress through the study. 584 
 585 
Figure 3. Sixty-month dissatisfaction-free survival analysis according to the treatment 586 
modality adopted: (solid line) oral contraceptive or progestin (n = 50); (dashed line) surgery (n = 587 
37) (log-rank test, 21 = 0.25; P = 0.61). Vertical tick marks are censored observations. 588 
